PREMPLUS KIT

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

CONJUGATED ESTROGENS; MEDROXYPROGESTERONE ACETATE

Pieejams no:

PFIZER CANADA ULC

ATĶ kods:

G03FA12

SNN (starptautisko nepatentēto nosaukumu):

MEDROXYPROGESTERONE AND ESTROGEN

Deva:

0.625MG; 5MG

Zāļu forma:

KIT

Kompozīcija:

CONJUGATED ESTROGENS 0.625MG; MEDROXYPROGESTERONE ACETATE 5MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

56(2X28 -2DIFF TABS)

Receptes veids:

Prescription

Ārstniecības joma:

ESTROGENS

Produktu pārskats:

Active ingredient group (AIG) number: 0242061002; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2019-11-06

Produkta apraksts

_Premplus _
®
_ and Premplus Cycle_
®
_ _
_Page 1 of 49_
PRODUCT MONOGRAPH
Pr
PREMPLUS
®
conjugated estrogens tablets CSD 0.625 mg and
medroxyprogesterone acetate tablets USP 2.5 mg, 5.0 mg
(Continuous therapy)
Pr
PREMPLUS CYCLE
®
conjugated estrogens tablets CSD 0.625 mg and
medroxyprogesterone acetate tablets USP 10.0 mg
(Cyclic therapy)
Estrogenic Hormones/Progestin
® Wyeth LLC
Pfizer Canada Inc., Licensee
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
DECEMBER 8, 2010
Submission Control No: 141329
_Premplus _
®
_ and Premplus Cycle_
®
_ _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT
INFORMATION...........................................................................3
INDICATIONS AND CLINICAL USE
................................................................................3
CONTRAINDICATIONS......................................................................................................4
WARNINGS AND PRECAUTIONS
....................................................................................4
ADVERSE REACTIONS
....................................................................................................14
DRUG INTERACTIONS
..................................................................................................22
DOSAGE AND ADMINISTRATION
................................................................................23
OVERDOSAGE...................................................................................................................24
ACTION AND CLINICAL
PHARMACOLOGY...............................................................25
STORAGE AND STABILITY
............................................................................................30
SPECIAL HANDLING
INSTRUCTIONS..........................................................................30
DOSAGE FORMS, COMPOSITION AND
PACKAGING................................................30
P